logo
Extinct Dire Wolf Has Been Resurrected, Company Claims—Here's What We Know

Extinct Dire Wolf Has Been Resurrected, Company Claims—Here's What We Know

Forbes07-04-2025

Ancient DNA from the dire wolf, a species that has been extinct for at least 10,000 years, now lives on in three pups whose genes were edited by Colossal Biosciences to restore the 'once-eradicated species through the science of de-extinction' in what the company says is its latest genetic breakthrough.
Scientists from Colossal said they rewrote the common gray wolf's genetic code to match the dire wolf genome from preserved DNA, and used domestic dogs as surrogate mothers to birth three pups: Romulus, Remus and Khaleesi.
The dire wolf's claimed return is being lauded by some as the first successful de-extinction effort of an animal whose live gene pool has been gone for thousands of years, though some experts are skeptical, with NewScientist reporting the wolves are really just genetically modified gray wolves that look kind of like dire wolves based on the limited gene edits made.
In March, the Dallas-based lab genetically engineered a brand new animal, the woolly mouse, to test connections between certain DNA sequences and specific traits of the extinct woolly mammoth, such as shaggy fur and accelerated metabolisms for cold weather.
The woolly mouse was a step toward bringing the woolly mammoth back to life, which has been a goal of the company since its founding in 2021, along with reviving the dodo and Tasmanian tiger.
The dire wolf was the largest mammal in the dog family during the Late Pleistocene period, 129,000 to 11,700 years ago. The first fossils were found in the Ohio River in 1854, according to the National Parks Service. The wolf's skull could reach 12 inches and while its size mimicked today's largest gray wolves, its teeth were larger.
Colossal, valued at $10.2 billion after a January funding round, was founded by Ben Lamm, whom Forbes values at $3.7 billion, and Harvard geneticist George Church, who does not have an equity stake in the company.
Colossal is researching how it can provide conservation value by using similar techniques to preserve endangered species. The company told Time it is in advanced discussions with the state of North Carolina about 'conservation tools that can be used to help rescue the red wolf and accelerate its recovery.' The National Wildlife Federation classifies the red wolf as an endangered species. Colossal told Forbes in March it is also in talks with an island nation about biodiversity contracts to use the controversial science for the preservation of endangered species, but it did not specify which country and said no agreements were signed yet.
While bringing a species back from extinction using genetic engineering is significant, experts remain skeptical about using the tactic to address biodiversity or climate change. 'I think that bringing back the mammoth is ill-advised, ill-thought-through and a stunt to attract investments in their company,' Karl Flessa, a professor of geosciences at the University of Arizona, told Forbes in February. 'Releasing genetically modified organisms into the environment—what could go wrong?'
Meet The Billionaire CEO Trying To Resurrect The Woolly Mammoth (Forbes)
The Return of the Dire Wolf (Time)
What Is a Dire Wolf? How Formerly Extinct Species Compares to Gray Wolves (Newsweek)
One Community. Many Voices. Create a free account to share your thoughts.
Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.
In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil.
Your post will be rejected if we notice that it seems to contain:
User accounts will be blocked if we notice or believe that users are engaged in:
So, how can you be a power user?
Thanks for reading our community guidelines. Please read the full list of posting rules found in our site's Terms of Service.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SpaceX readies private launch of four astronauts to International Space Station
SpaceX readies private launch of four astronauts to International Space Station

Yahoo

time3 hours ago

  • Yahoo

SpaceX readies private launch of four astronauts to International Space Station

Four crew members are set to launch Wednesday on a privately funded mission to the International Space Station. The flight, organized by the Houston-based company Axiom Space, is slated to lift off at 8 a.m. ET from NASA's Kennedy Space Center in Florida. The foursome will journey into orbit in a SpaceX Crew Dragon capsule atop a Falcon 9 rocket. NASA will broadcast live coverage of the launch beginning at 7:05 a.m. ET on NASA+. The flight was scheduled to launch Tuesday but high winds along the Florida coast forced a one-day delay. The mission, known as Ax-4, is expected to last about two weeks at the International Space Station. The mission will be led by retired NASA astronaut Peggy Whitson, who has already logged a record 675 days in space — more than any other American astronaut. Joining her will be pilot Shubhanshu Shukla, an astronaut with the Indian Space Research Organization; mission specialist Sławosz Uznański-Wiśniewski, a Polish scientist with the European Space Agency; and mission specialist Tibor Kapu, a mechanical engineer from Hungary. Shukla, Uznański-Wiśniewski and Kapu will make history by becoming the first people from their countries to live and work on the International Space Station. During their two-week stay at the orbiting lab, the Ax-4 crew members will conduct a host of scientific experiments, according to NASA, including studies of muscle regeneration, how sprouts and edible microalgae grow in microgravity and how tiny aquatic organisms survive at the ISS. If the launch goes according to plan, the four astronauts will dock at the space station on Thursday at around 12:30 p.m. ET. The upcoming flight will be Axiom Space's fourth crewed mission to the International Space Station. The company's first private expedition to the ISS was in 2022 with an all-civilian crew. The price tag for the Ax-4 mission has not been publicly disclosed, but space tourists reportedly paid around $55 million per seat on previous Axiom Space expeditions. This article was originally published on

Caris Life Sciences files for $424M IPO
Caris Life Sciences files for $424M IPO

Yahoo

time3 hours ago

  • Yahoo

Caris Life Sciences files for $424M IPO

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Precision medicine company Caris Life Sciences said Monday it expects to raise as much as $423.5 million in an initial public offering. The Irving, Texas-based company plans to list its common stock on the Nasdaq market under the symbol 'CAI,' offering 23.5 million shares at $16 to $18 each. Primarily focused on cancer, Caris' molecular profiling tools use artificial intelligence and machine learning algorithms to analyze disease for early detection, diagnosis, monitoring, therapy selection and drug development. Caris saw year-over-year revenue growth of about 50%, to $120.9 million, in the first quarter of 2025, driven primarily by its molecular profiling services, according to a securities filing. The company received Food and Drug Administration approval for its companion diagnostic test MI Cancer Seek in November. The test identifies cancer patients who may benefit from targeted treatments. Founded in 2008, Caris has identified about 915,000 unique pathogenic mutations to date, of which only about 17,000 were previously known, the company said in its filing. 'We can now identify a person's circulating pathogenic mutations and enable the design of a customized individualized therapy to that specific set of mutations,' David Dean Halbert, Caris founder and CEO, said in the filing. 'We believe this is going to create the opportunity for physicians to use our solutions to effectively prevent various chronic diseases before they ever get started at the earliest of stages.' In April, when the company closed a private funding round worth $168 million, it said it had raised a total of $1.86 billion in capital since 2018. Caris is among a handful of companies exploring a public offering in a medtech IPO market that's showing signs of emerging from a slump. Medical products supplier Medline has said it could go public, and Medtronic plans to separate its diabetes business into a standalone company, potentially through an IPO. Recommended Reading The medtech IPO window is finally open. Or is it? Sign in to access your portfolio

Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics awarded £860k grant for colorectal cancer diagnostic

Yahoo

time7 hours ago

  • Yahoo

Tagomics awarded £860k grant for colorectal cancer diagnostic

Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store